Vyome Holdings, Inc. (HIND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has a cash flow conversion efficiency ratio of 1.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.34 Million) by net assets ($3.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vyome Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Vyome Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Vyome Holdings, Inc. carry for a breakdown of total debt and financial obligations.
Vyome Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyome Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B.A.G Films and Media Limited
NSE:BAGFILMS
|
-0.017x |
|
Ynvisible Interactive Inc
V:YNV
|
-0.605x |
|
Baltic Classifieds Group PLC
LSE:BCG
|
0.085x |
|
Energy Focu
NASDAQ:EFOI
|
-0.018x |
|
ZIGUP plc
LSE:ZIG
|
0.224x |
|
Gaxos.ai Inc
NASDAQ:GXAI
|
-0.080x |
|
Techcential International Ltd
TWO:6616
|
0.038x |
|
Atlantic Sapphire As
OL:ASA
|
-0.180x |
Annual Cash Flow Conversion Efficiency for Vyome Holdings, Inc. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Vyome Holdings, Inc. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Vyome Holdings, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1625.07% |
| 2021-12-31 | $44.33 Million | $-15.38 Million | -0.347x | +41.23% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.19% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.16% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.